The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer

In clinical decision‐making, to decide the indication for adjuvant chemotherapy for estrogen receptor‐positive (ER+), human epidermal growth factor receptor‐2‐negative (HER2−), and node‐negative (n0) breast cancer patients, the accurate estimation of recurrence risk is essential. Unfortunately, conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Naoi, Yasuto, Tsunashima, Ryo, Shimazu, Kenzo, Noguchi, Shinzaburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019222/
https://www.ncbi.nlm.nih.gov/pubmed/33544932
http://dx.doi.org/10.1111/cas.14838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019222/
https://www.ncbi.nlm.nih.gov/pubmed/33544932
http://dx.doi.org/10.1111/cas.14838

Ejemplares similares